Endocrine Prevention of Breast Cancer
Author Information
Author(s): I.S. Fentiman
Primary Institution: ICRF Clinical Oncology Unit, Guy's Hospital
Hypothesis
Can hormonal modulation prevent the development of breast cancer?
Conclusion
Tamoxifen may reduce the incidence of breast cancer, but there are risks associated with its use.
Supporting Evidence
- Tamoxifen has been shown to reduce new primary breast cancers in treated groups.
- 1.4% of the tamoxifen group developed endometrial carcinoma compared to 0.2% in controls.
- Over 80% of patients in a pilot study complied with tamoxifen treatment.
Takeaway
This article discusses how tamoxifen might help prevent breast cancer, but it also points out that it can cause other health issues.
Methodology
The article reviews existing studies on tamoxifen's effects on breast cancer prevention.
Potential Biases
Potential bias due to reliance on existing studies and the complexity of hormonal treatments.
Limitations
The article notes that the effectiveness of tamoxifen may vary and that not all women will benefit equally.
Participant Demographics
The article discusses both premenopausal and postmenopausal women, particularly those with a family history of breast cancer.
Statistical Information
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website